Free Trial

Amylyx Pharmaceuticals (AMLX) News Today

Amylyx Pharmaceuticals logo
$4.76 -0.26 (-5.18%)
(As of 11/15/2024 ET)
Amylyx Pharmaceuticals, Inc. stock logo
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,290,000 shares, a growth of 27.7% from the October 15th total of 1,010,000 shares. Based on an average daily trading volume, of 1,340,000 shares, the short-interest ratio is currently 1.0 days. Approximately 3.1% of the shares of the company are sold short.
Amylyx Pharmaceuticals Q3 2024 Financial Highlights
Amylyx Pharmaceuticals, Inc. stock logo
HC Wainwright Issues Positive Forecast for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price
HC Wainwright raised their price objective on Amylyx Pharmaceuticals from $8.00 to $12.00 and gave the company a "buy" rating in a research note on Friday.
Amylyx Pharmaceuticals, Inc. stock logo
Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday
Amylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Amylyx Pharmaceuticals, Inc. stock logo
abrdn plc Has $6.39 Million Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
abrdn plc boosted its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 1,567.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,972,242 shares of the company's stock aft
Amylyx Pharmaceuticals, Inc. stock logo
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Bank of America
Bank of America upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $4.20 to $10.00 in a research report on Wednesday.
Amylyx Pharmaceuticals, Inc. stock logo
Amylyx Pharmaceuticals (NASDAQ:AMLX) Receives "Buy" Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and set a $8.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Friday.
Amylyx Pharmaceuticals, Inc. stock logo
Millennium Management LLC Has $2.92 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
Millennium Management LLC decreased its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 38.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,535,178 shares of the company's stock after se
Amylyx Pharmaceuticals, Inc. stock logo
American Century Companies Inc. Reduces Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
American Century Companies Inc. cut its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 95.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,041 shares of the company's stock aft
Amylyx Pharmaceuticals, Inc. stock logo
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by AQR Capital Management LLC
AQR Capital Management LLC raised its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 2,768.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,340,943 shares of the company's stock aft
Amylyx Pharmaceuticals, Inc. stock logo
Insider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells 11,442 Shares of Stock
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Camille L. Bedrosian sold 11,442 shares of the stock in a transaction on Monday, September 30th. The shares were sold at an average price of $3.20, for a total value of $36,614.40. Following the completion of the transaction, the insider now directly owns 143,801 shares in the company, valued at approximately $460,163.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Amylyx Pharmaceuticals, Inc. stock logo
Almitas Capital LLC Makes New Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
Almitas Capital LLC purchased a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,903,851 shares of the company's stock, valued at approxi
Amylyx Pharmaceuticals, Inc. stock logo
XTX Topco Ltd Purchases New Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
XTX Topco Ltd purchased a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 210,612 shares of the company's stock, valued at appro
Amylyx Pharmaceuticals, Inc. stock logo
Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Declines By 24.4%
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 1,490,000 shares, a decline of 24.4% from the August 15th total of 1,970,000 shares. Approximately 3.6% of the company's stock are short sold. Based on an average trading volume of 1,600,000 shares, the short-interest ratio is currently 0.9 days.
Amylyx Pharmaceuticals, Inc. stock logo
Acadian Asset Management LLC Makes New Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
Acadian Asset Management LLC purchased a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,211,617 shares of the compan
Amylyx Pharmaceuticals, Inc. stock logo
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of "Hold" from Analysts
Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have been assigned an average rating of "Hold" from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and two have given a buy ra
Amylyx Pharmaceuticals, Inc. stock logo
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Purchases $220,000.00 in Stock
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) Director George M. Milne, Jr. acquired 100,000 shares of the firm's stock in a transaction on Tuesday, September 3rd. The shares were bought at an average cost of $2.20 per share, with a total value of $220,000.00. Following the completion of the acquisition, the director now owns 858,571 shares in the company, valued at $1,888,856.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Amylyx Pharmaceuticals, Inc. stock logo
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Significant Growth in Short Interest
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) saw a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 1,970,000 shares, an increase of 5.9% from the July 31st total of 1,860,000 shares. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is currently 1.2 days. Currently, 4.3% of the company's stock are short sold.
Amylyx Pharmaceuticals, Inc. stock logo
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Down 50.8% in July
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 1,860,000 shares, a decline of 50.8% from the July 15th total of 3,780,000 shares. Based on an average daily trading volume, of 1,730,000 shares, the short-interest ratio is currently 1.1 days. Approximately 4.1% of the shares of the company are short sold.
Amylyx Pharmaceuticals, Inc. stock logo
Amylyx Pharmaceuticals (AMLX) Scheduled to Post Quarterly Earnings on Thursday
Amylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing earnings before the market opens on Thursday, August 8, Zacks reports.
Get Amylyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.

JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

AMLX Media Mentions By Week

AMLX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AMLX
News Sentiment

0.50

0.56

Average
Medical
News Sentiment

AMLX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AMLX Articles
This Week

4

6

AMLX Articles
Average Week

Get Amylyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:AMLX) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners